Observations reported here suggest that Clinical Laboratory Improvement Amendments (CLIA)–certified c-MYC analysis and scoring of tumor biopsies may be necessary to accurately determine relative c-MYC expression levels, rather than analysis of genomic DNA or RNA alone. This evidence concerns the gene MYC and neoplasm.